AC Immune S.A.
NASDAQ:ACIUBiotechnology
+$0.04 today
- Market cap
- $214.74M
- Beta
- 1.56
- P/E (TTM)
- -2.9
- EPS (TTM)
- -$0.67
Volume 0.12M
Average 0.32M
ACIU Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
AC Immune S.A.NASDAQ: ACIU
Operating Margin · Q1 FY2026 · quarter ended Mar 2026
Operating margin widens to -1321.5%
Operating margin was -1321.5% in Q1 FY2026, up 635.0 pp from a year earlier. On a trailing-twelve-month basis it was -1749.0%, down 1566.4 pp year over year. Over 3 fiscal years it narrowed by 126.9 pp.
Context
- Operating margin widened in 2 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
What to watch
Whether operating margin reaches the consensus estimate from 2 analysts of -178.2% for the fiscal year ending Dec 2026, up from -1927.3% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -1321.5%+2940.6 pp QoQ
- Last fiscal yearDec 2025
- -1927.3%-1735.5 pp YoY
- LTMMar 2026
- -1749.0%-1566.4 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -1927.3%
- Year-over-year change
- -1735.5pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -1927.3% | -1735.5pp |
| FY2024 | 2024-12-31 | -191.8% | +170.5pp |
| FY2023 | 2023-12-31 | -362.3% | +1438.1pp |
| FY2022 | 2022-12-31 | -1800.4% | — |
| FY2021 | 2021-12-31 | — | — |
Operating Margin vs competitors
How ACIU compares with its peers on the latest reported figures
- ACIU's LTM Mar 2026 operating margin of -1749.0% is the 3rd highest of the 6 companies compared; the peer median is -7531.1%.
- Its year-over-year change of -1566.4 pp is the 3rd highest of 4, against a peer median of +27.0 pp.
- Over three fiscal years its change of -126.9 pp compares with a peer median of -7876.0 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | -17.4% | +27.0 pp | +22.2 pp | |
| LTM Mar 2026 | -67.6% | +43.4 pp | +422.4 pp | |
| LTM Mar 2026 | -1749.0% | -1566.4 pp | -126.9 pp | |
| LTM Mar 2026 | -7531.1% | — | — | |
| LTM Mar 2026 | -9396.6% | — | -15774.1 pp | |
| LTM Mar 2026 | -618909.7% | -64222.0 pp | -565818.0 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| Peer median (excluding ACIU) | -7531.1% | +27.0 pp | -7876.0 pp | |
Competitors are the stored peer set for ACIU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 3.94M | 14.8M | 27.31M | 3.57M |
| Cost of Revenue | 0 | 0 | 54.61M | 62.57M | 0 |
| Gross Profit | 0 | 3.94M | (39.81M) | (35.26M) | 3.57M |
| Gross Margin | — | 100.0% | -268.9% | -129.1% | 100.0% |
| Research & Development | 62.28M | 60.34M | 54.61M | 62.57M | 56.44M |
| Selling, General & Admin | 10.88M | 9.58M | 10.58M | 11.43M | 11.65M |
| Operating Expenses | 79.01M | 74.78M | 13.82M | 17.12M | 72.44M |
| Depreciation & Amortization | 2.41M | 2.36M | 2.22M | 2.16M | 2.5M |
| EBITDA | (70.01M) | (68.03M) | (51.83M) | (48.62M) | (67.75M) |
| EBITDA Margin | — | -1728.7% | -350.2% | -178.0% | -1896.2% |
| Operating Income | (79.01M) | (70.85M) | (53.62M) | (52.38M) | (68.86M) |
| Operating Margin | — | -1800.4% | -362.3% | -191.8% | -1927.3% |
| Interest Income | 6.49M | 69K | 1.04M | 3.2M | 1.87M |
| Interest Expense | 581K | 355K | 176K | 133K | 191K |
| Other Income / Expenses | 6.02M | 107K | (599K) | 1.47M | (1.58M) |
| Income Before Tax | (72.99M) | (70.74M) | (54.22M) | (50.91M) | (70.45M) |
| Pre-Tax Margin | — | -1797.7% | -366.3% | -186.4% | -1971.6% |
| Income Tax Expense | 3K | 13K | 10K | 3K | 0 |
| Net Income | (73M) | (70.75M) | (54.23M) | (50.92M) | (70.45M) |
| Net Margin | — | -1798.0% | -366.4% | -186.4% | -1971.6% |
| EPS (Basic) | (0.97) | (0.85) | (0.64) | (0.51) | (0.70) |
| EPS (Diluted) | (0.97) | (0.85) | (0.64) | (0.51) | (0.70) |
| Weighted Avg Shares | 74.95M | 83.55M | 84.69M | 99.69M | 100.75M |
| Weighted Avg Shares (Diluted) | 74.95M | 83.55M | 84.69M | 99.69M | 100.75M |
AC Immune S.A.
NASDAQ:ACIU
Intrinsic Alpha fair value
Locked
Current Price
$2.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.